Chemokine-based therapies for MS: How do we get there from here?

Trends in Immunology

Volumn 22, Issue 11, 2001, Pages 591-593

  Kivisäkk, Pia ^a   Trebst, Corinna ^a   Eckstein, David J ^b   Kerza Kwiatecki, Al P ^a   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5;

ALLERGIC ENCEPHALOMYELITIS; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DEMYELINATION; DISEASE ACTIVITY; GENE MUTATION; GLIA CELL; IMMUNOMODULATION; INFLAMMATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NERVE LESION; NONHUMAN; OLIGODENDROGLIA; PASSIVE IMMUNIZATION; RECEPTOR UPREGULATION; RECURRENT DISEASE; SIGNAL TRANSDUCTION; STAGING; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TISSUE REPAIR; TISSUE SPECIFICITY;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CENTRAL NERVOUS SYSTEM; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; HUMANS; INFLAMMATION; LEUKOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 0035499661     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)02056-7     Document Type: Conference Paper

References (0)